Sartorius (OTCMKTS:SARTF) Upgraded at Zacks Investment Research
Sartorius (OTCMKTS:SARTF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $192.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 12.28% from the company’s previous close.
According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Other analysts have also recently issued reports about the stock. ValuEngine raised shares of Sartorius from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. DZ Bank reaffirmed a “sell” rating on shares of Sartorius in a research note on Wednesday, May 15th.
Sartorius (OTCMKTS:SARTF) last issued its quarterly earnings data on Thursday, April 18th. The company reported $0.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.16. The firm had revenue of $494.79 million for the quarter, compared to analysts’ expectations of $439.53 million. Sartorius had a net margin of 10.28% and a return on equity of 18.90%. Equities research analysts expect that Sartorius will post 3.45 earnings per share for the current fiscal year.
There is no company description available for Sartorius AG.
Featured Article: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.